EP
RGNX icon

Essential Partners’s Regenxbio RGNX Stock Holding History

Essential Partners’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.25K Sell
605
-1,491
-71% -$12.4K ﹤0.01% 1366
2026
Q1 		$17.6K Sell
2,096
-1,184
-36% -$12.4K 0.01% 978
2025
Q4 		$47.2K Buy
3,280
+791
+32% +$9.86K 0.01% 621
2025
Q3 		$24K Buy
2,489
+656
+36% +$5.8K 0.01% 833
2025
Q2 		$15K Buy
+1,833
New +$15.3K 0.01% 748

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Essential Partners's RGNX Position: Q2 2026 in Review

Essential Partners reduced its Regenxbio (RGNX) stake by 71% in Q2 2026, selling an estimated $12.4K and leaving 605 shares worth $7.25K. The position accounts for ﹤0.01% of the portfolio, ranked #1366.

Essential Partners first reported a position in RGNX in Q2 2025 and has held it in 5 quarters since. The position peaked at $47.2K in Q4 2025. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

  • Essential Partners held 605 shares of Regenxbio worth $7.25K as of Q2 2026.
  • Essential Partners sold 1,491 Regenxbio shares in Q2 2026, an estimated $12.4K.
  • Regenxbio made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1366 holding.
  • Essential Partners first reported a position in Regenxbio in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Regenxbio position peaked at $47.2K in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.